文献速递冠心病血脂与心血管预防

秋水仙碱治疗启动时机与心肌梗死后心血管结局:COLCOT试验分析

Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
PubMed 文献 · Eur Heart J · 2020-01-01

该研究基于COLCOT试验,分析4661例心梗后30天内随机接受秋水仙碱或安慰剂的患者,按启动时机分为<3天、4-7天和>8天三组。中位随访22.7个月,<3天启动组主要终点风险显著降低(HR=0.52),而4-7天和>8天组无显著获益。结论提示心梗后早期院内启动秋水仙碱可改善心血管结局。

要点

  • 心梗后<3天启动秋水仙碱显著降低主要复合终点风险(HR=0.52)。
  • 4-7天或>8天启动秋水仙碱未显示显著获益。
  • 早期启动还降低需血运重建的心绞痛住院和冠脉血运重建风险。

核心结论

  • 心肌梗死后早期(<3天)院内启动秋水仙碱可显著降低心血管复合终点风险。

研究设计与样本

  • 基于COLCOT随机对照试验的二次分析,纳入4661例心梗后30天内随机接受秋水仙碱或安慰剂的患者。
  • 按治疗启动时机(TTI)分为<3天(1193例)、4-7天(720例)和>8天(2748例)三组。
  • 主要疗效终点为心血管死亡、复苏心脏骤停、心梗、卒中或需冠脉血运重建的紧急心绞痛住院的复合终点。
  • 采用多变量Cox回归模型分析TTI与结局的关系,中位随访22.7个月。

主要发现

  • <3天启动秋水仙碱组主要终点发生率显著低于安慰剂组(HR=0.52,95%CI 0.32-0.84)。
  • 4-7天启动组主要终点无显著差异(HR=0.96,95%CI 0.53-1.75)。
  • >8天启动组主要终点无显著差异(HR=0.82,95%CI 0.61-1.11)。
  • 早期启动还显著降低需血运重建的紧急心绞痛住院(HR=0.35)、所有冠脉血运重建(HR=0.63)及心血管死亡/复苏心脏骤停/心梗/卒中复合终点(HR=0.55,均P<0.05)。

关键数值与推荐

  • 主要终点:心血管死亡、复苏心脏骤停、心梗、卒中或需冠脉血运重建的紧急心绞痛住院的复合终点。
  • TTI分层:<3天、4-7天、>8天。
  • 早期启动(<3天)主要终点HR=0.52(95%CI 0.32-0.84)。

临床怎么用

  • 心梗后应尽早(住院期间,<3天)启动秋水仙碱以最大化心血管获益。
  • 延迟启动(超过3天)可能削弱秋水仙碱的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine. METHODS AND RESULTS: In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-treatment initiation was defined as the length of time between the index MI and the initiation of study medication. The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The relationship between endpoints and various TTI (<3, 4-7 and >8 days) was examined using multivariable Cox regression models. Amongst the 4661 patients included in this analysis, there were 1193, 720, and 2748 patients, respectively, in the three TTI strata. After a median follow-up of 22.7 months, there was a significant reduction in the incidence of the primary endpoint for patients in whom colchicine was initiated < Day 3 compared with placebo [hazard ratios (HR) = 0.52, 95% confidence intervals (CI) 0.32-0.84], in contrast to patients in whom colchicine was initiated between Days 4 and 7 (HR = 0.96, 95% CI 0.53-1.75) or > Day 8 (HR = 0.82, 95% CI 0.61-1.11). The beneficial effects of early initiation of colchicine were also demonstrated for urgent hospitalization for angina requiring revascularization (HR = 0.35), all coronary revascularization (HR = 0.63), and the composite of cardiovascular death, resuscitated cardiac arrest, MI, or stroke (HR = 0.55, all P < 0.05). CONCLUSION: Patients benefit from early, in-hospital initiation of colchicine after MI. TRIAL REGISTRATION: COLCOT ClinicalTrials.gov number, NCT02551094.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Bouabdallaoui N, Tardif JC, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020. PMID: 32860034. doi:10.1093/eurheartj/ehaa659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。